Sample stability:
-
5 days at 20-25 o C
-
14 days at 2-8 o C
-
3 months at -20 o C
Units: U/mL
| Reference interval: < 34 |
Uncertainty of Measurement: 5%
Principle : Sandwich type immunoassay with chemiluminescence detection
Reagents: Roche Elecsys CA19-9 II
Analyser: Cobas e801
The main use of CA 19-9 is the diagnosis and monitoring of pancreatic cancer.
Also may be elevated in oesophageal, colon, stomach, biliary tract, breast, and some ovarian (mucinous type) cancers.
Values > 34 U/mL are found in pancreatitis, liver disease, biliary tract diseases, thyroid disease and diffuse interstitial lung diseases.
About 25% of pancreatic cancers do not express high levels of CA 19-9.
CA 19-9 is not suitable as a screening test for use in primary diagnosis of pancreatic cancer.
Emails to chemicalpathologist@adhb.govt.nz will receive priority attention from the on-call chemical pathologist.
If the query concerns a specific patient please include the NHI number in your email.
If email is not a suitable option, please contact the on-call chemical pathologist via Lablink (Auckland City Hospital ext. 22000 or 09-3078995).
Individual chemical pathologists may be contacted but will not be available at all times.
After-hours : contact Lablink (Auckland City Hospital ext. 22000 or 09-3078995) or hospital operator for on duty staff after hours.
Dr Samarina Musaad (Clinical Lead) : SamarinaM@adhb.govt.nz ext. 22402
Dr Cam Kyle: CampbellK@adhb.govt.nz ext 22052
Dr Weldon Chiu: WeldonC@adhb.govt.nz ext. 23427
Dr Campbell Heron: CHeron@adhb.govt.nz ext. 23427
Dr Sakunthala Jayasinghe: Sakunthala@adhb.govt.nz ext. 23427
Send a separated SST tube, or at least 300 uL serum aliquot. Transport at 4 o C.